Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RGNX – REGENXBIO Inc.

Float Short %

11.76

Margin Of Safety %

Put/Call OI Ratio

0.83

EPS Next Q Diff

-0.19

EPS Last/This Y

1.33

EPS This/Next Y

1.39

Price

13.88

Target Price

31.25

Analyst Recom

1.42

Performance Q

52.59

Relative Volume

1.02

Beta

1.08

Ticker: RGNX



20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-13RGNX11.660.700.094503
2025-11-14RGNX11.510.700.024492
2025-11-17RGNX11.140.700.034490
2025-11-18RGNX11.240.695.144536
2025-11-19RGNX10.940.686.004506
2025-11-20RGNX10.850.700.004561
2025-11-21RGNX11.780.700.254574
2025-11-24RGNX12.230.800.103789
2025-11-25RGNX13.470.790.003816
2025-11-26RGNX13.260.781.753863
2025-12-01RGNX12.620.840.024245
2025-12-02RGNX12.220.840.004252
2025-12-03RGNX12.90.830.674259
2025-12-04RGNX12.980.831.304261
2025-12-05RGNX13.160.840.404304
2025-12-08RGNX13.20.850.344314
2025-12-09RGNX12.730.850.384340
2025-12-10RGNX13.080.841.444361
2025-12-11RGNX12.870.840.264360
2025-12-12RGNX13.880.830.874372
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-13RGNX11.64117.0242.8-3.20
2025-11-14RGNX11.5226.3240.7-3.20
2025-11-17RGNX11.1426.7237.1-3.20
2025-11-18RGNX11.2426.7243.6-3.20
2025-11-19RGNX10.9326.7237.5-3.20
2025-11-20RGNX10.8526.7241.1-3.20
2025-11-21RGNX11.8126.7256.9-3.20
2025-11-24RGNX12.2426.7248.1-3.20
2025-11-25RGNX13.4526.7258.0-3.26
2025-11-26RGNX13.2626.7240.1-3.26
2025-12-01RGNX12.6021.1233.4-3.26
2025-12-02RGNX12.2121.1237.4-3.26
2025-12-03RGNX12.8821.1250.8-3.26
2025-12-04RGNX12.9821.1243.6-3.26
2025-12-05RGNX13.1621.1244.5-3.26
2025-12-08RGNX13.2421.1- -3.26
2025-12-09RGNX12.7221.1236.4-3.26
2025-12-10RGNX13.0721.1246.4-3.26
2025-12-11RGNX12.8621.1239.8-3.26
2025-12-12RGNX13.8821.1254.5-3.26
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-13RGNX-1.29-2.269.83
2025-11-14RGNX-1.29-2.269.81
2025-11-17RGNX-0.84-1.839.86
2025-11-18RGNX-0.80-1.839.86
2025-11-19RGNX-0.80-1.839.86
2025-11-20RGNX-0.80-1.839.86
2025-11-21RGNX-0.80-1.839.86
2025-11-24RGNX-0.80-0.769.86
2025-11-25RGNX-0.80-0.769.86
2025-11-26RGNX-0.80-0.7610.28
2025-12-01RGNX-0.80-1.2110.28
2025-12-02RGNX-0.80-1.2110.28
2025-12-03RGNX-0.80-1.2110.28
2025-12-04RGNX-0.80-1.2110.28
2025-12-05RGNX-0.80-1.2110.28
2025-12-08RGNX-0.80-1.2210.28
2025-12-09RGNX-0.80-1.2210.28
2025-12-10RGNX-0.80-1.2211.76
2025-12-11RGNX-0.80-1.2211.76
2025-12-12RGNX-0.80-1.2211.76
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="RGNX" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS​

-1.2

Avg. EPS Est. Current Quarter

-0.8

Avg. EPS Est. Next Quarter

-1.39

Insider Transactions

-0.8

Institutional Transactions

-1.22

Beta

1.08

Average Sales Estimate Current Quarter

61

Average Sales Estimate Next Quarter

77

Fair Value

Quality Score

39

Growth Score

40

Sentiment Score

73

Actual DrawDown %

72.4

Max Drawdown 5-Year %

-89.4

Target Price

31.25

P/E

Forward P/E

PEG

P/S

4.35

P/B

4.35

P/Free Cash Flow

EPS

-3.49

Average EPS Est. Cur. Y​

-3.26

EPS Next Y. (Est.)

-1.87

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-110.29

Relative Volume

1.02

Return on Equity vs Sector %

-137.1

Return on Equity vs Industry %

-122.1

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.98

EBIT Estimation

254.5
[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”RGNX” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”RGNX” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”RGNX” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”RGNX” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”RGNX” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”RGNX” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”RGNX” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
REGENXBIO Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 353
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
stock quote shares RGNX – REGENXBIO Inc. Stock Price stock today
news today RGNX – REGENXBIO Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RGNX – REGENXBIO Inc. yahoo finance google finance
stock history RGNX – REGENXBIO Inc. invest stock market
stock prices RGNX premarket after hours
ticker RGNX fair value insiders trading